---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-023942"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:52:00.437671+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Dermata terminates Villani license, pivots to OTC skin care

## Summary
- Terminated license agreement with Villani Inc.; effective 90 days after Nov 17, 2025 notice.
- Eliminates future milestone payments of up to $40.5M and single-digit royalties.
- Strategic shift: will commercialize OTC skin care; withdrew XYNGARI IND.
- License covered exclusive rights to sponge-based products for skin disease treatments.

## SEC filing metadata
- accession: 0001493152-25-023942
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000149315225023942/0001493152-25-023942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000149315225023942/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-023942
- JSON: https://secwatch.observer/filing/0001493152-25-023942.json
- Plain text: https://secwatch.observer/filing/0001493152-25-023942.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.